The PDF of the full text is an interesting read. The expression of HER2 was only reported in very few of the trial participants. Most were noted to be -'ve or of unknown status and covered several different cancers. This trial was designed to see if an immune response did in fact occur to the HER2 target and whether it was safe to do so.
The HER-Vaxx study is more specific in that the participant must have HER2 expressing cancer of the colon. Can't wait to hear more about those results.
Ann: Clinical Cancer Research Journal publish B-Vaxx Phase 1 Data, page-12
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $386.7M | |||
| Open | High | Low | Value | Volume |
| 3.8¢ | 3.8¢ | 3.7¢ | $270.7K | 7.251M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 949810 | 3.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.8¢ | 2277658 | 11 |
View Market Depth
| Last trade - 16.10pm 26/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |
